![](https://endpts.com/wp-content/uploads/2021/04/Judy-Chou-AltruBio-tile-scaled.jpg)
Judy Chou, AltruBio CEO
AltruBio secures $225M for an updated version of its ulcerative colitis drug
Bay Area and Taipei biotech AltruBio has raised $225 million in a Series B to move forward its experimental drug for ulcerative colitis and other …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.